NuProbe Forms Scientific Advisory Board and Appoints New Director
July 24, 2018
CAMBRIDGE, Mass. – July 24, 2018 — NuProbe Global, an…
Read More
A breakthrough molecular strategy
NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world’s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.
Latest News
格微基因（NuProbe）成立科学顾问委员会并任命新董事
July 24, 2018
创新分子诊断公司格微基因（NuProbe）近期宣布成立科学顾问委员会并任命新董事。科学顾问委员会成员包括基因组学先驱哈佛大学遗传学教授George M. Church和哈佛大学医学院病理学教授David R. Walt。科学顾问委员会将参与指导公司未来战略和推进其技术平台。同时资深医疗界投资人, 博远资本创始合伙人陈鹏辉先生被任命为新董事。 “强大的早期诊断能力有助于有效治疗病人并减少手术。”创办了AbVitro, Editas Medicine和eGenesis在内的超过15家生物技术公司的George M….
NuProbe Announces $11 Million Series A Funding Round
April 23, 2018
Molecular diagnostics startup to expand reach of precision medicine. CAMBRIDGE,…
Global Founders
David Yu Zhang, Ph.D.
David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.
Victor Chenyang Shi, Ph.D.
Victor Shi, Ph.D., is a seasoned business executive, entrepreneur, and investor in diagnostics and biotech industry. He was the Founding President of Qiagen Asia Pacific and a former Professor at National University of Singapore.
Scientific Advisory Board
George M. Church, Ph.D.
George M. Church, Ph.D., is a Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard and MIT, and a Founding Member of the Wyss Institute for Biologically Inspired Engineering at Harvard. Dr. Church is also Director of the U.S. Department of Energy Technology Center, Director of the National Institutes of Health Center of Excellence in Genomic Science, and Director of the Personal Genome Project. His is the co-founder of more than 15 biotech companies including AbVitro, Editas Medicine, Veritas Genetics, Warpdrive Bio, eGenesis and ReadCoor. He is a member of the National Academy of Sciences, the National Academy of Engineering and the Franklin Bower Laureate for Achievement in Science. He received a B.A. in Zoology and Chemistry from Duke University and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.
- More
David R. Walt, Ph.D.
David R. Walt, Ph.D., is a member of the faculty at Harvard Medical School in the Department of Pathology at Brigham and Women’s Hospital, is a Member of the Wyss Institute, and is a Howard Hughes Medical Institute Professor. Previously, he was University Professor at Tufts University. Dr. Walt is the Scientific Founder of Illumina Inc. and Quanterix Corp. and has co-founded several other life sciences startups including Ultivue, Inc. and Arbor Biotechnologies. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a B.S. in Chemistry from the University of Michigan and a Ph.D. in Chemical Biology from SUNY at Stony Brook.
- More
OUR INVESTORS
Technology
NuProbe technology utilizes DNA toehold probe systems based on the fundamental engineering principle of molecular competition and precisely balanced thermodynamics and its application to rare allele detection.
Toehold probe design achieves near optimal specificity and is robust against environmental variation. Toehold probe designs improved qPCR and NGS mutation detection by 10-100 fold with sensitivity down to 0.01 percent and multiplexing capability of 10-100 multiplexed reactions with hundreds of mutations in the same test tube, enabling non-invasive early stage cancer cell-free DNA detection in blood plasma. We validated the technology with US patient samples, and are in the process of conducting preliminary clinical trials in China.
PCR
Nuprobe’s toehold probe designs improved qPCR mutation detection by 100 fold with sensitivity down to 0.01% with 10 validated multiplexing capabilities. This technology is verified with blood plasma samples from cancer patients.
Sequencing
NuProbe’s proprietary toehold probe technology provides an economic Sample-In Answer-Out (SIAO) solution in which cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations are integrated.
NGS
NuProbe’s unparalleled targeted variant enrichment probe set enables much greater sensitivity and higher sample throughput for next generation sequencing (NGS).